BackARS Pharmaceuticals Overview

ARS Pharmaceuticals Selling, General & Admin

See how SPRY's SG&A expenses trends over time vs similar companies.

Get informed when a big investor buys or sells

+ Follow

Quarterly SG&A Expenses

$72.20M
75.66% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$261.22M
149.22% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

ARS Pharmaceuticals (SPRY) FAQ

Stockcircle tracks selling, general & admin for ARS Pharmaceuticals (SPRY), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Selling, General & Admin page is built for ARS Pharmaceuticals's historical SG&A expenses trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use SG&A expenses as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main SPRY overview so you can move from this figure to the surrounding analysis quickly.